loading
전일 마감가:
$30.17
열려 있는:
$29.5
하루 거래량:
89,358
Relative Volume:
0.13
시가총액:
$1.91B
수익:
$87.56M
순이익/손실:
$-167.47M
주가수익비율:
-12.55
EPS:
-2.34
순현금흐름:
$-148.20M
1주 성능:
-3.09%
1개월 성능:
-4.51%
6개월 성능:
-34.83%
1년 성능:
-14.38%
1일 변동 폭
Value
$29.15
$29.79
1주일 범위
Value
$29.15
$31.47
52주 변동 폭
Value
$19.45
$53.27

Kymera Therapeutics Inc Stock (KYMR) Company Profile

Name
명칭
Kymera Therapeutics Inc
Name
전화
857-285-5314
Name
주소
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Name
직원
208
Name
트위터
Name
다음 수익 날짜
2025-02-21
Name
최신 SEC 제출 서류
Name
KYMR's Discussions on Twitter

KYMR을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
KYMR
Kymera Therapeutics Inc
29.38 1.95B 87.56M -167.47M -148.20M -2.34
Biotechnology icon
ONC
Beigene Ltd Adr
242.25 24.41B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
433.96 111.55B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.33 42.47M 0 0 0 0.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
585.45 63.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
VRNA
Verona Pharma Plc Adr
74.16 5.92B 0 -153.72M -103.81M -2.00

Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-03-13 개시 Citigroup Buy
2024-12-10 개시 BTIG Research Buy
2024-12-06 개시 BMO Capital Markets Market Perform
2024-12-02 업그레이드 Wells Fargo Equal Weight → Overweight
2024-11-18 개시 Stephens Overweight
2024-09-09 재개 Leerink Partners Outperform
2024-08-26 업그레이드 Wolfe Research Peer Perform → Outperform
2024-04-22 개시 Oppenheimer Outperform
2024-02-15 개시 Wolfe Research Peer Perform
2024-01-04 업그레이드 JP Morgan Neutral → Overweight
2024-01-03 다운그레이드 BofA Securities Buy → Neutral
2023-12-19 다운그레이드 Wells Fargo Overweight → Equal Weight
2023-06-30 개시 Truist Buy
2023-05-05 업그레이드 Raymond James Mkt Perform → Outperform
2022-12-06 다운그레이드 Credit Suisse Outperform → Neutral
2022-11-08 개시 Raymond James Mkt Perform
2022-08-15 개시 Jefferies Buy
2022-08-03 개시 Goldman Buy
2022-07-20 개시 SVB Leerink Mkt Perform
2022-04-28 개시 Credit Suisse Outperform
2022-03-10 개시 JP Morgan Neutral
2022-02-10 개시 Wells Fargo Overweight
2021-09-30 개시 B. Riley Securities Neutral
2021-09-30 개시 Stifel Buy
2021-09-10 다운그레이드 BofA Securities Buy → Neutral
2021-05-21 개시 UBS Buy
2021-04-14 개시 Berenberg Buy
2020-12-04 개시 H.C. Wainwright Buy
2020-09-15 개시 BofA Securities Neutral
2020-09-15 개시 Cowen Outperform
2020-09-15 개시 Guggenheim Buy
2020-09-15 개시 Morgan Stanley Equal-Weight
모두보기

Kymera Therapeutics Inc 주식(KYMR)의 최신 뉴스

pulisher
May 20, 2025

Kymera Therapeutics (KYMR) Receives 'Buy' Rating from Stifel with $55 Price Target | KYMR Stock News - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Kymera Therapeutics (KYMR) Gains Buy Rating from Stifel with Promising Outlook | KYMR Stock News - GuruFocus

May 20, 2025
pulisher
May 19, 2025

Kymera Therapeutics (KYMR) Showcases Promising Preclinical Data for Asthma Treatment | KYMR Stock News - GuruFocus

May 19, 2025
pulisher
May 19, 2025

Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the American Thoracic Society International Conference - The Manila Times

May 19, 2025
pulisher
May 19, 2025

Kymera’s KT-621 shows promise in preclinical asthma study - Investing.com

May 19, 2025
pulisher
May 19, 2025

Kymera’s KT-621 shows promise in preclinical asthma study By Investing.com - Investing.com Nigeria

May 19, 2025
pulisher
May 19, 2025

Kymera Therapeutics presents preclinical data for KT-621 - TipRanks

May 19, 2025
pulisher
May 19, 2025

Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the American Thoracic Society International Conference | KYMR Stock News - GuruFocus

May 19, 2025
pulisher
May 19, 2025

Breakthrough: New Oral Asthma Drug Shows Superior Results to Dupilumab in Latest Clinical Data - Stock Titan

May 19, 2025
pulisher
May 14, 2025

Transcript : Kymera Therapeutics, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 03 - marketscreener.com

May 14, 2025
pulisher
May 14, 2025

Kymera at BofA Conference: Strategic FDA and Manufacturing Insights By Investing.com - Investing.com Nigeria

May 14, 2025
pulisher
May 14, 2025

Kymera at BofA Conference: Strategic FDA and Manufacturing Insights - Investing.com

May 14, 2025
pulisher
May 14, 2025

Kymera TherapeuticsIntriguing Degradation Thesis, But A Bit Powder Puff (NASDAQ:KYMR) - Seeking Alpha

May 14, 2025
pulisher
May 13, 2025

Kymera Therapeutics (KYMR) Target Price Adjusted by UBS | KYMR S - GuruFocus

May 13, 2025
pulisher
May 13, 2025

UBS Adjusts Price Target on Kymera Therapeutics to $70 From $72, Maintains Buy Rating - marketscreener.com

May 13, 2025
pulisher
May 13, 2025

Kymera Therapeutics (KYMR) Target Price Revised by UBS | KYMR St - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Analysts Are Betting On Kymera Therapeutics, Inc. (NASDAQ:KYMR) With A Big Upgrade This Week - simplywall.st

May 13, 2025
pulisher
May 13, 2025

When the Price of (KYMR) Talks, People Listen - news.stocktradersdaily.com

May 13, 2025
pulisher
May 12, 2025

The Analyst Verdict: Kymera Therapeutics In The Eyes Of 4 Experts - Benzinga

May 12, 2025
pulisher
May 12, 2025

Kymera Therapeutics (KYMR) Receives Reaffirmed 'Buy' Rating from - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Kymera Therapeutics (KYMR) Stock Rating Maintained, Price Target - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Kymera Therapeutics (KYMR) Faces Price Target Reduction Amid Str - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Truist maintains Kymera Therapeutics stock buy rating and $35 target By Investing.com - Investing.com UK

May 12, 2025
pulisher
May 12, 2025

Kymera unveils new oral IRF5 degrader for immuno-inflammatory diseases - BioWorld MedTech

May 12, 2025
pulisher
May 12, 2025

B. Riley Adjusts Kymera Therapeutics Price Target to $38 From $41, Maintains Neutral Rating - marketscreener.com

May 12, 2025
pulisher
May 12, 2025

BofA Adjusts Price Target for Kymera Therapeutics (KYMR) | KYMR Stock News - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Kymera Therapeutics: Promising Pipeline and Strategic Decisions Justify Buy Rating - TipRanks

May 12, 2025
pulisher
May 10, 2025

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q1 2025 Earnings Call Transcript - Insider Monkey

May 10, 2025
pulisher
May 10, 2025

Kymera Therapeutics Inc (KYMR) Q1 2025 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance

May 10, 2025
pulisher
May 10, 2025

Kymera advances oral drug for autoimmune diseases - Investing.com

May 10, 2025
pulisher
May 10, 2025

Kymera Therapeutics Inc (KYMR) Q1 2025 Earnings Call Highlights: Strategic Advances and Financial Resilience - GuruFocus

May 10, 2025
pulisher
May 10, 2025

Kymera Therapeutics (NASDAQ:KYMR) Shares Gap Up on Strong Earnings - Defense World

May 10, 2025
pulisher
May 10, 2025

Decoding Kymera Therapeutics Inc (KYMR): A Strategic SWOT Insigh - GuruFocus

May 10, 2025
pulisher
May 10, 2025

Kymera advances oral drug for autoimmune diseases By Investing.com - Investing.com India

May 10, 2025
pulisher
May 10, 2025

Earnings call transcript: Kymera Therapeutics beats EPS forecast in Q1 2025 - Investing.com

May 10, 2025
pulisher
May 09, 2025

Kymera (KYMR) Financial Update: Strong Cash Position Supports Future Developments | KYMR Stock News - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Kymera Therapeutics Reports Strong Pipeline Progress - TipRanks

May 09, 2025
pulisher
May 09, 2025

Kymera Therapeutics (KYMR) Launches Innovative Oral Immunology P - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Kymera Therapeutics Inc (KYMR) Q1 2025 Earnings: Revenue Soars t - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Kymera Therapeutics Announces First Quarter 2025 Financial Resul - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Kymera Therapeutics (KYMR) Surpasses Revenue Estimates with Stro - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Kymera Therapeutics Expands Industry Leading Immunology Pipeline - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Kymera Therapeutics’ Earnings Call: Resilience and Strategic Growth - TipRanks

May 09, 2025
pulisher
May 09, 2025

Earnings call transcript: Kymera Therapeutics beats EPS forecast in Q1 2025 By Investing.com - Investing.com South Africa

May 09, 2025
pulisher
May 09, 2025

Truist maintains Buy on Kymera stock, reiterates $53 target By Investing.com - Investing.com Canada

May 09, 2025
pulisher
May 09, 2025

Kymera Therapeutics Q1 2025 Earnings Call Transcript - MarketBeat

May 09, 2025
pulisher
May 09, 2025

Kymera' s Q1 Loss Narrower Than Expected, Pipeline Progress Encouraging - Zacks Investment Research

May 09, 2025
pulisher
May 09, 2025

Kymera (KYMR) Financial Update: Strong Cash Position Supports Fu - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Kymera Therapeutics, Inc. (KYMR) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance

May 09, 2025
pulisher
May 09, 2025

Kymera Therapeutics Q1 Loss Widens, Collaboration Revenue Rises - marketscreener.com

May 09, 2025
pulisher
May 09, 2025

Kymera Therapeutics Inc (KYMR) Q1 2025 Earnings: Revenue Soars to $22.1M, Beating Estimates; Net Loss Widens - GuruFocus

May 09, 2025

Kymera Therapeutics Inc (KYMR) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$1.19
price down icon 13.67%
$31.50
price down icon 3.35%
$578.71
price down icon 0.54%
$284.71
price down icon 1.54%
$4.10
price down icon 2.24%
$72.94
price down icon 0.11%
자본화:     |  볼륨(24시간):